


IN THE CLAIMS

The status of each claim is listed below:

Claims 1-208: Canceled.

209. (Previously Presented) A compound represented by formula (I):




wherein

X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;

Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or -N(R²)₂;


R¹ is hydrogen or lower alkyl;

each R² is, independently, -R⁷, -(CH₂)_m-OR⁸, -(CH₂)_m-NR⁷R¹⁰, -(CH₂)_n(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -(CH₂CH₂O)_m-R⁸, -(CH₂CH₂O)_m-CH₂CH₂NR⁷R¹⁰, -(CH₂)_n-C(=O)NR⁷R¹⁰, -(CH₂)_n-Z_g-R⁷, -(CH₂)_m-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -(CH₂)_n-CO₂R⁷, or




R³ and R⁴ are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower (alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or

pyridyl- lower alkyl, with the proviso that at least one of R^3 and R^4 is a group represented by formula (A):



wherein

each R^{L} is, independently, $-\text{R}^7$, $-(\text{CH}_2)_n-\text{OR}^8$, $-\text{O}-(\text{CH}_2)_m-\text{OR}^8$, $-(\text{CH}_2)_n-\text{NR}^7\text{R}^{10}$, $-\text{O}-(\text{CH}_2)_m-\text{NR}^7\text{R}^{10}$, $-(\text{CH}_2)_n(\text{CHOR}^8)(\text{CHOR}^8)_n-\text{CH}_2\text{OR}^8$, $-\text{O}-(\text{CH}_2)_m(\text{CHOR}^8)(\text{CHOR}^8)_n-\text{CH}_2\text{OR}^8$, $-(\text{CH}_2\text{CH}_2\text{O})_m-\text{R}^8$, $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m-\text{R}^8$, $-(\text{CH}_2\text{CH}_2\text{O})_m-\text{CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$, $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m-\text{CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$, $-(\text{CH}_2)_n-\text{C}(=\text{O})\text{NR}^7\text{R}^{10}$, $-\text{O}-(\text{CH}_2)_m-\text{C}(=\text{O})\text{NR}^7\text{R}^{10}$, $-(\text{CH}_2)_n-(\text{Z})_g-\text{R}^7$, $-\text{O}-(\text{CH}_2)_m-(\text{Z})_g-\text{R}^7$, $-(\text{CH}_2)_n-\text{NR}^{10}-\text{CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n-\text{CH}_2\text{OR}^8$, $-\text{O}-(\text{CH}_2)_m-\text{NR}^{10}-\text{CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n-\text{CH}_2\text{OR}^8$, $-(\text{CH}_2)_n-\text{CO}_2\text{R}^7$, $-\text{O}-(\text{CH}_2)_m-\text{CO}_2\text{R}^7$, $-\text{OSO}_3\text{H}$, $-\text{O-glucuronide}$, $-\text{O-glucose}$,



each o is, independently, an integer from 0 to 10;

each p is an integer from 0 to 10;


with the proviso that the sum of o and p in each contiguous chain is from 1 to 10;

each x is, independently, O , NR^{10} , $\text{C}(=\text{O})$, CHOH , $\text{C}(=\text{N}-\text{R}^{10})$, $\text{CHNR}^7\text{R}^{10}$, or represents a single bond;

each R^5 is, independently, $-\text{O}-\text{CH}_2-(\text{C}=\text{O})\text{NH}-(\text{C}=\text{O})\text{CH}_3$, $-(\text{CH}_2)_n-(\text{C}=\text{NH})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{NH}-\text{C}(=\text{NH})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{CONHCH}_2(\text{CHOH})_n-\text{CH}_2\text{OH}$, $-\text{NH}-\text{C}(=\text{O})-$

CH₂-(CHOH)_nCH₂OH, -NH-(C=O)-NH-CH₂(CHOH)_nCHOH, -O-(CH₂)_m-NH-C(=NH)-N(R⁷)₂, -O-(CH₂)_m-CHNH₂-CONR⁷R¹⁰, -O-CH₂CHOHCH₂O-glucuronide, -OCH₂CO₂H, -NHCH₂(CHOH)₂-CH₂OH, -OCH₂CO₂Et, -NHSO₂CH₃, -O-CH₂C(=O)NH₂, -CH₂NH₂, -NHCO₂Et, -OCH₂CH₂CH₂CH₂OH, -CH₂NHSO₂CH₃, -OCH₂CH₂CHOHCH₂OH, -OCH₂CH₂NHCO₂Et, -NH-C(=NH₂)-NH₂, -CH₂CH-CH-CH₂OH, -CH₂-CHOH-CH₂-NHBoc, -O-CH₂-CHOH-CH₂-NHBoc, -OCH₂CH₂CH₂NH₂, -OCH₂CH₂NHCH₂(CHOH)₂CH₂OH, -OCH₂CH₂NH(CH₂[(CHOH)₂CH₂OH])₂, -(CH₂)₄-NHBoc, -(CH₂)₄-NH₂, -(CH₂)₄-OH, -OCH₂CH₂NHSO₂CH₃, -(CH₂)₃-NHBoc, -(CH₂)₃NH₂, -O-CH₂-CHOH-CH₂-NH-C(=NH)-N(R⁷)₂, para-(CH₂)₄-OH, para-O-(CH₂)₄-OH, para-NHSO₂CH₃, para-CH₂NH(C=O)O-C(CH₃)₃, para-NH(C=O)CH₃, para-CH₂NH₂, para-NH-CO₂C₂H₅, para-CH₂NH(C=O)CH₃, para-CH₂NHCO₂CH₃, para-CH₂NHSO₂CH₃, para-(CH₂)₄-NH(C=O)OC(CH₃)₃, para-(CH₂)₄-NH₂, para-(CH₂)₃-NH(C=O)OC(CH₃)₃, para-(CH₂)₃-NH₂, para-OCH₂CH₂NHCO₂C(CH₃)₃, para-OCH₂CH₂NHCO₂C₂H₅, para-O-(CH₂)₃-NH-CO₂C(CH₃)₃, para-O(CH₂)₃-NH₂, para-OCH₂CH₂NHSO₂CH₃, para-OCH₂CHOHCH₂O-glucuronide, para-OCH₂CH₂CHOHCH₂OH, para-OCH₂-(α-CHOH)₂CH₂OH, para-OCH₂-(CHOH)₂CH₂OH, para-C(=O)NH₂, para-O-CH₂-(C(=O)NHCH₂CHOH, para-O-CH₂-(C(=O)NHCH₂CHOHCH₂OH, para-O-CH₂(C(=O)NHCH₂(CHOH)₂CH₂OH, para-O-CH₂(C(=O)NHSO₂CH₃, para-O-CH₂(C(=O)NHCO₂CH₃, para-O-CH₂-(C(=O)NH-C(C(=O)NH₂, para-(C=NH)-NH₂, para-(CH₂)₃-NH-C(=NH)-NH₂, para-CH₂NH-C(=NH)-NH₂, para-NH(C=O)NHCH₂CH₂OH, para-O(CH₂)₃-NH-C(=NH)-NH₂, para-OCH₂-CHNH₂-CONH₂, para-OCH₂CHOH-CH₂NHCO₂C(CH₃)₃, para-NHCH₂(CHOH)₂CH₂OH, para-OCH₂CO₂C(CH₃)₃, para-OCH₂CO₂H, or para-OCH₂CO₂C₂H₅;


each R⁶ is, independently, -R⁷, -OR¹¹, -N(R⁷)₂, -(CH₂)_m-OR⁸, -O-(CH₂)_m-OR⁸, -(CH₂)_n-NR⁷R¹⁰, -O-(CH₂)_m-NR⁷R¹⁰, -(CH₂)_n(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -O-(CH₂)_m(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -(CH₂CH₂O)_m-R⁸, -O-(CH₂CH₂O)_m-R⁸, -(CH₂CH₂O)_m-CH₂CH₂NR⁷R¹⁰, -O-(CH₂CH₂O)_m-CH₂CH₂NR⁷R¹⁰, -(CH₂)_n-C(=O)NR⁷R¹⁰, -O-(CH₂)_m-C(=O)NR⁷R¹⁰, -(CH₂)_n-(Z)_g-R⁷, -O-(CH₂)_m-(Z)_g-R⁷, -(CH₂)_n-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -O-(CH₂)_m-NR¹⁰-CH₂(CHOR⁸)(CHOR⁸)_n-CH₂OR⁸, -(CH₂)_n-CO₂R⁷, -O-(CH₂)_m-CO₂R⁷, -OSO₃H, -O-glucuronide, -O-glucose,



wherein when two R^6 are $-\text{OR}^{11}$ and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two R^6 may be bonded together to form a methylenedioxy group;

each R^7 is, independently, hydrogen or lower alkyl;

each R^8 is, independently, hydrogen, lower alkyl, $-\text{C}(=\text{O})-\text{R}^{11}$, glucuronide, 2-tetrahydropyranyl, or



each R^9 is, independently, $-\text{CO}_2\text{R}^7$, $-\text{CON}(\text{R}^7)_2$, $-\text{SO}_2\text{CH}_3$, or $-\text{C}(=\text{O})\text{R}^7$;

each R^{10} is, independently, $-\text{H}$, $-\text{SO}_2\text{CH}_3$, $-\text{CO}_2\text{R}^7$, $-\text{C}(=\text{O})\text{NR}^7\text{R}^9$, $-\text{C}(=\text{O})\text{R}^7$, or $-\text{CH}_2-(\text{CHOH})_n-\text{CH}_2\text{OH}$;

each Z is, independently, CHOH , $\text{C}(=\text{O})$, $\text{CHNR}^7\text{R}^{10}$, $\text{C}=\text{NR}^{10}$, or NR^{10} ;

each R^{11} is, independently, lower alkyl;

each g is, independently, an integer from 1 to 6;

each m is, independently, an integer from 1 to 7;

each n is, independently, an integer from 0 to 7;

each Q is, independently, $\text{C}-\text{R}^5$, $\text{C}-\text{R}^6$, or a nitrogen atom, wherein at most three Q in a ring are nitrogen atoms;

or a pharmaceutically acceptable salt thereof, and

inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

210. (Previously Presented) The compound of Claim 209, wherein Y is $-\text{NH}_2$.

211. (Previously Presented) The compound of Claim 210, wherein R^2 is hydrogen.
212. (Previously Presented) The compound of Claim 211, wherein R^1 is hydrogen.
213. (Previously Presented) The compound of Claim 212, wherein X is chlorine.
214. (Previously Presented) The compound of Claim 213, wherein R^3 is hydrogen.
215. (Previously Presented) The compound of Claim 214, wherein each R^L is hydrogen.
216. (Previously Presented) The compound of Claim 215, wherein o is 4.
217. (Previously Presented) The compound of Claim 216, wherein p is 0.
218. (Previously Presented) The compound of Claim 217, wherein x represents a single bond.
219. (Previously Presented) The compound of Claim 218, wherein each R^6 is hydrogen.
220. (Previously Presented) The compound of Claim 219, wherein at most one Q is a nitrogen atom.
221. (Previously Presented) The compound of Claim 220, wherein no Q is a nitrogen atom.
222. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $(CH_2)_4-OH$.
223. (Previously Presented) The compound of Claim 209, wherein R^5 is para-O- $(CH_2)_4-OH$.

224. (Previously Presented) The compound of Claim 209, wherein R^5 is para-NHSO₂CH₃.

225. (Previously Presented) The compound of Claim 209, wherein R^5 is para-CH₂NH(C=O)-OC(CH₃)₃.

226. (Previously Presented) The compound of Claim 209, wherein R^5 is para-NH(C=O)CH₃.

227. (Previously Presented) The compound of Claim 209, wherein R^5 is para-CH₂NH₂.

228. (Previously Presented) The compound of Claim 209, wherein R^5 is para-NH-CO₂C₂H₅.

229. (Previously Presented) The compound of Claim 209, wherein R^5 is para-CH₂NH(C=O)CH₃.

230. (Previously Presented) The compound of Claim 209, wherein R^5 is para-CH₂NHCO₂CH₃.

231. (Previously Presented) The compound of Claim 209, wherein R^5 is para-CH₂NHSO₂CH₃.

232. (Previously Presented) The compound of Claim 209, wherein R^5 is para-(CH₂)₄-NH(C=O)OC(CH₃)₃.

233. (Previously Presented) The compound of Claim 209, wherein R^5 is para-(CH₂)₄-NH₂.

234. (Previously Presented) The compound of Claim 209, wherein R^5 is para-(CH₂)₃-NH(C=O)OC(CH₃)₃.

235. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $(CH_2)_3-NH_2$.

236. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2CH_2NHCO_2C(CH_3)_3$.

237. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2CH_2NHCO_2C_2H_5$.

238. (Previously Presented) The compound of Claim 209, wherein R^5 is para-O- $(CH_2)_3-NH-CO_2-C(CH_3)_3$.

239. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $O(CH_2)_3-NH_2$.

240. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2CH_2NHCO_2CH_3$.

241. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2CHOHCH_2O$ -glucuronide.


242. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2CH_2CHOHCH_2OH$.

243. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2-(\alpha-CHOH)_2CH_2OH$.

244. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2-(CHOH)_2CH_2OH$.

245. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $C(=O)NH_2$.

246. (Previously Presented) The compound of Claim 209, which is represented by the formula:



247. (Previously Presented) The compound of Claim 209, which is the methane sulfonic acid salt.

248. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-O-CH₂-(C=O)NHCH₂CHOH.

249. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-O-CH₂-(C=O)NHCH₂CHOHCH₂OH.

250. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-O-CH₂-(C=O)NHCH₂(CHOH)₂CH₂OH.

251. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-O-CH₂-(C=O)NHSO₂CH₃.

252. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-O-CH₂-(C=O)NHCO₂CH₃.

253. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-O-CH₂-(C=O)NH-C(C=O)NH₂.

254. (Previously Presented) The compound of Claim 209, wherein R⁵ is -O-CH₂-(C=O)NH-(C=O)CH₃.

255. (Previously Presented) The compound of Claim 209, wherein R⁵ is (CH₂)_n-(C=NH)-NH₂.

256. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-(C=NH)-NH₂.


257. (Previously Presented) The compound of Claim 209, wherein R⁵ is (CH₂)_n-NH-C(=NH)-NH₂.

258. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-(CH₂)₃-NH-C(=NH)-NH₂.

259. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-CH₂NH-C(=NH)-NH₂.


260. (Previously Presented) The compound of Claim 209, wherein R⁵ is (CH₂)_n-CONHCH₂(CHOH)_n-CH₂OH.

261. (Previously Presented) The compound of Claim 209, which is represented by the formula:



262. (Previously Presented) The compound of Claim 209, wherein R⁵ is NH-C(=O)-CH₂-(CHOH)_nCH₂OH.

263. (Previously Presented) The compound of Claim 209, which is represented by the formula:




264. (Previously Presented) The compound of Claim 209, wherein R^5 is $-NH-(C=O)-NH-CH_2(CHOH)_nCHOH$.

265. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $NH(C=O)NHCH_2CH_2OH$.

266. (Previously Presented) The compound of Claim 209, wherein R^5 is $-O-(CH_2)_m-NH-C(=NH)-N(R^7)_2$.

267. (Previously Presented) The compound of Claim 209, which is represented by the formula:



268. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $O(CH_2)_3-NH-C(=NH)-NH_2$.

269. (Previously Presented) The compound of Claim 209, wherein R^5 is $-O-(CH_2)_m-CHNH_2-CONR^7R^{10}$.

270. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2-CHNH_2-CONH_2$.


271. (Previously Presented) The compound of Claim 209, which is the (R) enantiomer.

272. (Previously Presented) The compound of Claim 209, which is the (S) enantiomer.


273. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-OCH₂CHOH-CH₂NHCO₂C(CH₃)₃.

274. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-NHCH₂(CHOH)₂CH₂OH.


275. (Previously Presented) The compound of Claim 209, which is represented by the formula:




276. (Previously Presented) The compound of Claim 209, which is represented by the formula:




277. (Previously Presented) The compound of Claim 209, which is represented by the formula:



278. (Previously Presented) The compound of Claim 209, which is represented by the formula:



279. (Previously Presented) The compound of Claim 209, which is represented by the formula:



280. (Previously Presented) The compound of Claim 209, wherein R^5 is para- $OCH_2CO_2C(CH_3)_3$.

281. (Previously Presented) The compound of Claim 209, wherein R^5 is para- OCH_2CO_2H .

282. (Previously Presented) The compound of Claim 209, wherein R⁵ is para-OCH₂CO₂C₂H₅.

283. (Previously Presented) The compound of Claim 209, wherein

X is halogen;

Y is -N(R⁷)₂;

R¹ is hydrogen or C₁-C₃ alkyl;

R² is -R⁷, -(CH₂)_m-OR⁸, or -(CH₂)_n-CO₂R⁷;

R³ is a group represented by formula (A); and

R⁴ is hydrogen, a group represented by formula (A), or lower alkyl.

284. (Previously Presented) The compound of Claim 209, wherein

X is chloro or bromo;

Y is -N(R⁷)₂;

R² is hydrogen or C₁-C₃ alkyl;

at most three R⁶ are other than hydrogen as defined above;

at most three R^L are other than hydrogen as defined above; and

at most 2 Q are nitrogen atoms.

285. (Previously Presented) The compound of Claim 209, wherein Y is -NH₂.

286. (Previously Presented) The compound of Claim 209, wherein R⁴ is hydrogen;

at most one R^L is other than hydrogen as defined above;

at most two R⁶ are other than hydrogen as defined above; and

at most 1 Q is a nitrogen atom.

287. (Previously Presented) The compound of Claim 209, wherein R⁵ is

-O-CH₂CHOHCH₂O-glucuronide,

-OCH₂CO₂H,

-NHCH₂(CHOH)₂-CH₂OH,

-OCH₂CO₂Et,

-NHSO₂CH₃,

-O-CH₂C(=O)NH₂,

-CH₂NH₂,

-NHCO₂Et,
-OCH₂CH₂CH₂CH₂OH,
-CH₂NHSO₂CH₃,
-OCH₂CH₂CHOHCH₂OH,
-OCH₂CH₂NHCO₂Et,
-NH-C(=NH₂)-NH₂,
-CH₂CH-CH-CH₂OH,
-CH₂-CHOH-CH₂-NHBoc,
-O-CH₂-CHOH-CH₂-NHBoc,
-OCH₂CH₂CH₂NH₂,
-OCH₂CH₂NHCH₂(CHOH)₂CH₂OH,
-OCH₂CH₂NH(CH₂[(CHOH)₂CH₂OH])₂,
-(CH₂)₄-NHBoc,
-(CH₂)₄-NH₂,
-(CH₂)₄-OH,
-OCH₂CH₂NHSO₂CH₃,
-(CH₂)₃-NH Boc,
-(CH₂)₃NH₂, or
-O-CH₂-CHOH-CH₂-NH-C(=NH)-N(R⁷)₂.

288. (Previously Presented) The compound of Claim 209, wherein

X is chloro or bromo;

Y is -N(R⁷)₂;

R¹ is hydrogen or C₁-C₃ alkyl;

R² is hydrogen or C₁-C₃ alkyl;

R³ is a group represented by formula (A); and

R⁴ is hydrogen, a group represented by formula (A), or lower alkyl;

at most three R⁶ are other than hydrogen as defined above;

at most three R^L are other than hydrogen as defined above; and

at most 2 Q are nitrogen atoms.

289. (Previously Presented) The compound of Claim 288, wherein
R⁴ is hydrogen;
at most one R^L is other than hydrogen as defined above;
at most two R⁶ are other than hydrogen as defined above; and
at most 1 Q is a nitrogen atom.

290. (Previously Presented) The compound of Claim 289, wherein
X is chloro or bromo;
Y is -N(R⁷)₂;
R¹ is hydrogen or C₁-C₃ alkyl;
R² is hydrogen or C₁-C₃ alkyl;
R³ is a group represented by formula (A); and
R⁴ is hydrogen, a group represented by formula (A), or lower alkyl;
at most three R⁶ are other than hydrogen as defined above;
at most three R^L are other than hydrogen as defined above; and
at most 2 Q are nitrogen atoms.

291. (Previously Presented) The compound of Claim 290, wherein
R⁴ is hydrogen;
at most one R^L is other than hydrogen as defined above;
at most two R⁶ are other than hydrogen as defined above; and
at most 1 Q is a nitrogen atom.

292. (Previously Presented) The compound of Claim 209, wherein x is a single bond.

293. (Previously Presented) The compound of Claim 209, which is in the form of a pharmaceutically acceptable salt.

294. (Previously Presented) A composition, comprising:
the compound of Claim 209; and
a P2Y₂ receptor agonist.

295. (Previously Presented) A composition, comprising:
the compound of Claim 209; and
a bronchodilator.

296. (Previously Presented) A pharmaceutical composition, comprising the
compound of Claim 209 and a pharmaceutically acceptable carrier.

297. (Previously Presented) A method of promoting hydration of mucosal surfaces,
comprising:
administering an effective amount of the compound of Claim 209 to a mucosal
surface of a subject.

298. (Previously Presented) A method of restoring mucosal defense, comprising:
topically administering an effective amount of the compound of Claim 209 to a
mucosal surface of a subject in need thereof.

299. (Previously Presented) A method of blocking sodium channels, comprising:
contacting sodium channels with an effective amount of the compound of Claim 209.

300. (Previously Presented) A method of treating chronic bronchitis, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need
thereof.

301. (Previously Presented) A method of treating cystic fibrosis, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need
thereof.

302. (Previously Presented) A method of treating sinusitis, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need
thereof.

303. (Previously Presented) A method of treating vaginal dryness, comprising:
administering an effective amount of the compound of Claim 209 to the vaginal tract
of a subject in need thereof.

304. (Previously Presented) A method of treating dry eye, comprising:
administering an effective amount of the compound of Claim 209 to the eye of a
subject in need thereof.

305. (Previously Presented) A method of promoting ocular hydration, comprising:
administering an effective amount of the compound of Claim 209 to the eye of a
subject.

306. (Previously Presented) A method of promoting corneal hydration, comprising:
administering an effective amount of the compound of Claim 209 to the eye of a
subject.

307. (Previously Presented) A method of promoting mucus clearance in mucosal
surfaces, comprising:
administering an effective amount of the compound of Claim 209 to a mucosal
surface of a subject.

308. (Previously Presented) A method of treating Sjogren's disease, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need
thereof.

309. (Previously Presented) A method of treating distal intestinal obstruction
syndrome, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need
thereof.

310. (Previously Presented) A method of treating dry skin, comprising:
administering an effective amount of the compound of Claim 209 to the skin of a
subject in need thereof.

311. (Previously Presented) A method of treating esophagitis, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need
thereof.

312. (Previously Presented) A method of treating dry mouth (xerostomia), comprising:
administering an effective amount of the compound of Claim 209 to the mouth of a subject in need thereof.

313. (Previously Presented) A method of treating nasal dehydration, comprising:
administering an effective amount of the compound of Claim 209 to the nasal passages of a subject in need thereof.

314. (Previously Presented) The method of Claim 211, wherein the nasal dehydration is brought on by administering dry oxygen to the subject.

315. (Previously Presented) A method of preventing ventilator-induced pneumonia , comprising:
administering an effective amount of the compound of Claim 209 to a subject on a ventilator.

316. (Previously Presented) A method of treating asthma, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need thereof.

317. (Previously Presented) A method of treating primary ciliary dyskinesia, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need thereof.

318. (Previously Presented) A method of treating otitis media, comprising:
administering an effective amount of the compound of Claim 209 to a subject in need thereof.

319. (Previously Presented) A method of inducing sputum for diagnostic purposes, comprising:

administering an effective amount of the compound of Claim 209 to a subject in need thereof.

320. (Previously Presented) A method of treating chronic obstructive pulmonary disease, comprising:

administering an effective amount of the compound of Claim 209 to a subject in need thereof.

321. (Previously Presented) A method of treating emphysema, comprising:

administering an effective amount of the compound of Claim 209 to a subject in need thereof.

322. (Previously Presented) A method of treating pneumonia, comprising:

administering an effective amount of the compound of Claim 209 to a subject in need thereof.

323. (Previously Presented) A method of treating constipation, comprising:

administering an effective amount of the compound of Claim 209 to a subject in need thereof.

324. (Previously Presented) The method of Claim 321, wherein the compound is administered orally or via a suppository or enema.

325. (Previously Presented) A method of treating chronic diverticulitis, comprising:

administering an effective amount of the compound of Claim 209 to a subject in need thereof.

326. (Previously Presented) A method of treating rhinosinusitis, comprising:

administering an effective amount of the compound of Claim 209 to a subject in need thereof.

327. (Previously Presented) A method of treating hypertension, comprising administering the compound of Claim 209 to a subject in need thereof.

328. (Previously Presented) A method of reducing blood pressure, comprising administering the compound of Claim 209 to a subject in need thereof.

329. (Previously Presented) A method of treating edema, comprising administering the compound of Claim 209 to a subject in need thereof.

330. (Previously Presented) A method of promoting diuresis, comprising administering the compound of Claim 209 to a subject in need thereof.

331. (Previously Presented) A method of promoting natriuresis, comprising administering the compound of Claim 209 to a subject in need thereof.

332. (Previously Presented) A method of promoting saluresis, comprising administering the compound of Claim 209 to a subject in need thereof.

333. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $(CH_2)_4-OH$.

334. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $O-(CH_2)_4-OH$.

335. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $NHSO_2CH_3$.

336. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $CH_2NH(C=O)-OC(CH_3)_3$.

337. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $NH(C=O)CH_3$.

338. (Previously Presented) The compound of Claim 221, wherein R^5 is para- CH_2NH_2 .

339. (Previously Presented) The compound of Claim 221, wherein R^5 is para-NH- $CO_2C_2H_5$.

340. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $CH_2NH(C=O)CH_3$.

341. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $CH_2NHCO_2CH_3$.

342. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $CH_2NHCO_2CH_3$.

343. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $(CH_2)_4-NH(C=O)OC(CH_3)_3$.

344. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $(CH_2)_4-NH_2$.

345. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $(CH_2)_3-NH(C=O)OC(CH_3)_3$.

346. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $(CH_2)_3-NH_2$.

347. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $OCH_2CH_2NHCO_2C(CH_3)_3$.

348. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $OCH_2CH_2NHCO_2C_2H_5$.

349. (Previously Presented) The compound of Claim 221, wherein R^5 is para-O-(CH₂)₃-NH-CO₂-C(CH₃)₃.

350. (Previously Presented) The compound of Claim 221, wherein R^5 is para-O(CH₂)₃-NH₂.

351. (Previously Presented) The compound of Claim 221, wherein R^5 is para-OCH₂CH₂NHSO₂CH₃.

352. (Previously Presented) The compound of Claim 221, wherein R^5 is para-OCH₂CHOHCH₂O-glucuronide.

353. (Previously Presented) The compound of Claim 221, wherein R^5 is para-OCH₂CH₂CHOHCH₂OH.

354. (Previously Presented) The compound of Claim 221, wherein R^5 is para-OCH₂-(α -CHOH)₂CH₂OH.

355. (Previously Presented) The compound of Claim 221, wherein R^5 is para-OCH₂-(CHOH)₂CH₂OH.

356. (Previously Presented) The compound of Claim 221, wherein R^5 is para-C(=O)NH₂.

357. (Previously Presented) The compound of Claim 221, which is the methane sulfonic acid salt.

358. (Previously Presented) The compound of Claim 221, wherein R^5 is para-O-CH₂-(C=O)NHCH₂CHOH.

359. (Previously Presented) The compound of Claim 221, wherein R^5 is para-O-CH₂-(C=O)NHCH₂CHOHCH₂OH.

360. (Previously Presented) The compound of Claim 221, wherein R^5 is para-O- $CH_2(C=O)NHCH_2(CHOH)_2CH_2OH$.

361. (Previously Presented) The compound of Claim 221, wherein R^5 is para-O- $CH_2(C=O)NHSO_2CH_3$.

362. (Previously Presented) The compound of Claim 221, wherein R^5 is para-O- $CH_2(C=O)NHCO_2CH_3$.

363. (Previously Presented) The compound of Claim 221, wherein R^5 is para-O- $CH_2-(C=O)NH-C(C=O)NH_2$.

364. (Previously Presented) The compound of Claim 221, wherein R^5 is -O- $CH_2-(C=O)NH-(C=O)CH_3$.

365. (Previously Presented) The compound of Claim 221, wherein R^5 is $(CH_2)_n-(C=NH)-NH_2$.

366. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $(C=NH)-NH_2$.

367. (Previously Presented) The compound of Claim 221, wherein R^5 is $(CH_2)_n-NH-C(=NH)-NH_2$.

368. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $(CH_2)_3-NH-C(=NH)-NH_2$.

369. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $CH_2NH-C(=NH)-NH_2$.

370. (Previously Presented) The compound of Claim 221, wherein R^5 is $(CH_2)_n-CONHCH_2(CHOH)_n-CH_2OH$.

371. (Previously Presented) The compound of Claim 221, wherein R^5 is $\text{NH-C(=O)-CH}_2\text{-(CHOH)}_n\text{CH}_2\text{OH}$.

372. (Previously Presented) The compound of Claim 221, wherein R^5 is $\text{-NH-(C=O)-NH-CH}_2\text{(CHOH)}_n\text{CHOH}$.

373. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $\text{NH(C=O)NHCH}_2\text{CH}_2\text{OH}$.

374. (Previously Presented) The compound of Claim 221, wherein R^5 is $\text{-O-(CH}_2)_m\text{-NH-C(=NH)-N(R}^7)_2$.

375. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $\text{O(CH}_2)_3\text{-NH-C(=NH)-NH}_2$.

376. (Previously Presented) The compound of Claim 221, wherein R^5 is $\text{-O-(CH}_2)_m\text{-CHNH}_2\text{-CONR}^7\text{R}^{10}$.

377. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $\text{OCH}_2\text{-CHNH}_2\text{-CONH}_2$.

378. (Currently Amended) The compound of Claim ~~377~~ 221, which is the (R) enantiomer.

379. (Currently Amended) The compound of Claim ~~377~~ 221, which is the (S) enantiomer.

380. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $\text{OCH}_2\text{CHOH-CH}_2\text{NHCO}_2\text{C(CH}_3)_3$.

381. (Previously Presented) The compound of Claim 221, wherein R^5 is para- $\text{NHCH}_2\text{(CHOH)}_2\text{CH}_2\text{OH}$.

382. (Previously Presented) The compound of Claim 221, wherein R⁵ is para-OCH₂CO₂C(CH₃)₃.

383. (Previously Presented) The compound of Claim 221, wherein R⁵ is para-OCH₂CO₂H.

384. (Previously Presented) The compound of Claim 221, wherein R⁵ is para-OCH₂CO₂C₂H₅.

Claims 385-388: Canceled.

389. (Previously Presented) The compound of Claim 221, wherein R⁵ is

-O-CH₂CHOHCH₂O-glucuronide,
-OCH₂CO₂H,
-NHCH₂(CHOH)₂-CH₂OH,
-OCH₂CO₂Et,
-NHSO₂CH₃,
-O-CH₂C(=O)NH₂,
-CH₂NH₂,
-NHCO₂Et,
-OCH₂CH₂CH₂CH₂OH,
-CH₂NHSO₂CH₃,
-OCH₂CH₂CHOHCH₂OH,
-OCH₂CH₂NHCO₂Et,
-NH-C(=NH₂)-NH₂,
-CH₂CH-CH-CH₂OH,
-CH₂-CHOH-CH₂-NHBoc,
-O-CH₂-CHOH-CH₂-NHBoc,
-OCH₂CH₂CH₂NH₂,
-OCH₂CH₂NHCH₂(CHOH)₂CH₂OH,
-OCH₂CH₂NH(CH₂[(CHOH)₂CH₂OH])₂,
-(CH₂)₄-NHBoc,
-(CH₂)₄-NH₂,
-(CH₂)₄-OH,

- Application Serial No: 10/532,110

-OCH₂CH₂NHSO₂CH₃,
-(CH₂)₃-NH Boc,
-(CH₂)₃NH₂, or
-O-CH₂-CHOH-CH₂-NH-C(=NH)-N(R⁷)₂.

Claims 390-394: Canceled.

395. (Previously Presented) The compound of Claim 221, which is in the form of a pharmaceutically acceptable salt.

396. (Previously Presented) The compound of Claim 270, which is the (R) enantiomer.

397. (Previously Presented) The compound of Claim 270, which is the (S) enantiomer.